Ipamorelin (CAS 170851-70-4), also known by its developmental code NNC-26-0161, is a synthetic pentapeptide growth hormone secretagogue with the molecular formula C38H49N9O5 and a molecular weight of 711.86 g/mol. Defined by the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, Ipamorelin incorporates an alpha-aminoisobutyric acid (Aib) residue at position 1 and a D-2-Naphthylalanine residue at position 3, structural features that distinguish it from earlier generation secretagogues. Produced via solid-phase peptide synthesis, NNC-26-0161 acts as a selective agonist at the ghrelin receptor (GHS-R1a) and is widely referenced in preclinical growth hormone research.

Ipamorelin has been extensively investigated in preclinical endocrinology and receptor pharmacology research. In vitro receptor pharmacology studies in pituitary cell models have examined its binding characteristics at the GHS-R1a receptor, with published research documenting GH-related signalling pathway activation without concurrent stimulation of adrenocorticotropic hormone (ACTH) or cortisol release in comparative secretagogue panels including GHRP-6 and GHRP-2 [1]. Rodent model studies have further investigated the compound’s interaction with pituitary somatotroph populations, examining dose-response characteristics of GH-mediated effects under controlled experimental conditions [2]. Ipamorelin’s selectivity profile has made it a key reference compound in structure-activity relationship research across the secretagogue class.

Ipamorelin is manufactured in a cGMP compliant laboratory to a guaranteed purity of 98% or above. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

Editorial Team

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed and approved 14 June 2026

View credentials →